Experimental evaluation of bioequivalenceт of the original and generic peptide drugs in multiple sclerosis

• DOI: 10.18454/acen.2018.2.6
• Publication Date: 2025-01-31T21:04:01Z
• Authors: Marya S. Ryabtseva; Natalya P. Neugodova; Tamara A. Batuash...; Ludmila V. Simutenko
• Keywords: Bioequivalence

Multiple sclerosis is a chronic, widespread neurodegenerative disease, which accompanied by considerable degree of disability and requires lifelong drug therapy. In this regard, the relevant objective for production generic drugs treating multiple sclerosis, so-called generics, to ensure their quality be at level original forms. This article provides an overview methods determining comparability generics major groups medications used in treatment sclerosis: glatiramer acetate preparations, mitoxantrone, monoclonal antibodies, immunomodulating agents, preparations based on interferon-. Experimental allergic encephalomyelitis, standard model verifying specific activity was as example analyze factors that impair consistent assessment generics. Approaches standardization monitoring effectiveness group were suggested.